tiprankstipranks
Trending News
More News >
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
US Market
Advertisement

TriSalus Life Sciences (TLSI) AI Stock Analysis

Compare
65 Followers

Top Page

TLSI

TriSalus Life Sciences

(NASDAQ:TLSI)

Rating:47Neutral
Price Target:
$5.00
▼(-2.91% Downside)
The overall stock score is primarily influenced by financial performance challenges, including negative equity and cash flow issues. While there are positive aspects such as revenue growth and strategic corporate events, the financial instability and unattractive valuation weigh heavily on the score.
Positive Factors
Financial Guidance
The company reiterated guidance for revenue growth in 2025 of 50%+, which is expected to be driven by continued commercial efforts in liver-directed therapies.
Product Development
TriNav system adoption continues to expand as more real-world data and health economic research demonstrate improved clinical outcomes, particularly in complex disease/patient settings and has more favorable economics for providers.
Negative Factors
Cash Flow Expectations
Investments in TriNav commercial efforts have led the company to no longer expect cash flow positivity in FY25, now expected in the first half of 2026.
Financial Performance
Gross margin of 83.9% missed our 86% estimate, and adjusted EBITDA of ($5.3M) also missed our ($4.3M) estimate.

TriSalus Life Sciences (TLSI) vs. SPDR S&P 500 ETF (SPY)

TriSalus Life Sciences Business Overview & Revenue Model

Company DescriptionTriSalus Life Sciences (TLSI) is a biotechnology company focused on developing innovative therapies and delivery systems for the treatment of solid tumors. Operating within the pharmaceutical and healthcare sectors, the company specializes in immuno-oncology and drug delivery technologies. Its core offerings include proprietary drug delivery platforms and therapeutic agents designed to enhance the effectiveness of cancer treatments.
How the Company Makes MoneyTriSalus Life Sciences generates revenue through the development and commercialization of its proprietary drug delivery systems and therapeutic agents. The company earns income by licensing its technologies to pharmaceutical partners and through the sale of its products. Key revenue streams include licensing fees, royalties from partnered drugs, and direct sales of its therapies and delivery systems. Significant partnerships with leading pharmaceutical companies and healthcare providers contribute to its earnings by expanding the reach and application of its technologies.

TriSalus Life Sciences Earnings Call Summary

Earnings Call Date:Aug 12, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with significant revenue growth, successful product launches, and strategic capital raises. However, there were challenges with gross margin decline, increased administrative expenses, and a delay in achieving EBITDA positivity. Overall, the positive aspects of growth and expansion outweigh the financial setbacks.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
TriSalus Life Sciences reported $11.2 million in net sales for Q2 2025, marking a 52% increase compared to Q2 2024 and a 22% sequential gain over Q1 2025.
Launch of TriNav FLX Infusion System
The company successfully launched the TriNav FLX infusion system, which has demonstrated improved trackability and is engineered for use in tortuous vascular anatomy.
Expansion of Product Portfolio
TriSalus expanded its product suite with the launch of TriNav LD and TriGuide for larger vessels, and the full commercial launch of TriNav FLX.
Successful Capital Raise
TriSalus completed a $22 million private placement with healthcare-focused institutional investors, strengthening its balance sheet.
Increased Unique Ordering Accounts
The number of unique ordering accounts increased by 28% year-over-year.
New Reimbursement Code for TriNav
Centers for Medicare and Medicaid Services issued code C8004, providing coverage for simulation or mapping procedures using TriNav.
Reduction in Operating Losses
Operating losses for Q2 2025 were reduced to $7.3 million from $8.2 million in Q2 2024.
Negative Updates
Gross Margin Decline
Gross margin was 84% for the quarter, down from 88% in Q2 2024, primarily due to lower manufacturing efficiency associated with newly launched products.
Increased G&A Expenses
General and administrative expenses increased to $5.7 million in Q2 2025 from $4 million in Q2 2024, driven by $1 million of nonrecurring legal and audit expenses.
Delay in EBITDA Positivity
EBITDA positivity and cash flow positivity are delayed until early 2026 due to strategic investments in the business.
Company Guidance
During TriSalus Life Sciences' second quarter 2025 earnings call, the company reported strong financial performance with $11.2 million in net sales, marking a 52% increase year-over-year and a 22% sequential gain. The company highlighted the successful launch of the TriNav FLX infusion system and completion of a $22 million private placement. Gross margin for the quarter was 84%, down slightly from 88% in the previous year, attributed to lower manufacturing efficiency with new products. Operating losses decreased to $7.3 million from $8.2 million in Q2 2024, and adjusted EBITDA loss improved to $5.3 million. TriSalus reiterated its guidance for 50% revenue growth and expects to achieve cash flow positivity in early 2026. The company is advancing its TriNav product portfolio, expanding clinical applications, and focusing on partnership opportunities for nelitolimod to preserve long-term value while minimizing development expenses.

TriSalus Life Sciences Financial Statement Overview

Summary
TriSalus Life Sciences exhibits strong revenue growth but faces significant financial challenges, including persistent losses, negative equity, and reliance on external financing. These factors indicate substantial risks related to profitability and cash flow sustainability.
Income Statement
45
Neutral
TriSalus Life Sciences has shown significant revenue growth over the years, with a 73% increase from 2022 to 2023 and a 59% increase from 2023 to 2024. However, the company remains unprofitable, with consistent negative net income and negative EBIT and EBITDA margins, indicating ongoing operational and profitability challenges.
Balance Sheet
30
Negative
The balance sheet reveals a problematic financial structure with substantial negative stockholders' equity, indicating that liabilities exceed assets. High levels of debt relative to equity suggest potential solvency concerns, although the debt-to-equity calculation is not feasible due to negative equity. The equity ratio is negative, reinforcing the company's financial instability.
Cash Flow
40
Negative
The cash flow statement highlights significant negative operating cash flows, which indicate challenges in generating cash from core operations. Despite a positive trend in financing cash flows, free cash flow remains negative, pointing to ongoing cash burn and reliance on external financing to sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue32.14M29.43M18.51M12.40M8.40M5.43M
Gross Profit27.51M25.33M15.91M10.14M7.21M3.24M
EBITDA-22.02M-36.16M-58.30M-46.76M-23.57M-25.32M
Net Income-27.21M-33.23M-59.04M-47.19M-28.84M-31.83M
Balance Sheet
Total Assets28.63M23.97M25.73M22.00M37.84M252.01M
Cash, Cash Equivalents and Short-Term Investments13.00M8.53M11.78M9.41M30.30M4.49M
Total Debt33.12M23.63M1.59M1.96M544.00K42.18M
Total Liabilities62.99M49.87M51.66M198.32M167.44M23.50M
Stockholders Equity-34.37M-25.89M-25.94M-176.33M30.90M228.52M
Cash Flow
Free Cash Flow-35.51M-41.19M-51.17M-33.10M-23.95M-1.22M
Operating Cash Flow-34.48M-40.84M-50.58M-32.31M-22.70M-677.60K
Investing Cash Flow-993.00K-345.00K-2.12M-1.79M-2.26M-250.00M
Financing Cash Flow44.50M37.94M54.63M13.46M50.77M252.01M

TriSalus Life Sciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.15
Price Trends
50DMA
4.69
Positive
100DMA
5.03
Positive
200DMA
5.00
Positive
Market Momentum
MACD
0.18
Negative
RSI
58.83
Neutral
STOCH
61.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLSI, the sentiment is Positive. The current price of 5.15 is above the 20-day moving average (MA) of 4.63, above the 50-day MA of 4.69, and above the 200-day MA of 5.00, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 58.83 is Neutral, neither overbought nor oversold. The STOCH value of 61.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TLSI.

TriSalus Life Sciences Risk Analysis

TriSalus Life Sciences disclosed 88 risk factors in its most recent earnings report. TriSalus Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

TriSalus Life Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$202.15M-92.33%23.11%18.06%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
50
Neutral
$243.82M-87.65%2.47%56.93%
47
Neutral
$257.32M271.41%45.50%53.07%
47
Neutral
$145.25M-350.22%29.34%-283.53%
44
Neutral
$38.18M-68.32%93.07%13.25%
$84.68M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TLSI
TriSalus Life Sciences
5.15
-0.07
-1.34%
MYO
Myomo
1.01
-2.76
-73.21%
OM
Outset Medical
13.35
5.68
74.05%
LNSR
LENSAR
12.17
7.71
172.87%
CVRX
CVRx
7.70
-0.82
-9.62%
BDMD
Baird Medical Investment Holdings
2.35
-8.69
-78.71%

TriSalus Life Sciences Corporate Events

Executive/Board Changes
TriSalus Life Sciences Grants CFO Stock Options
Neutral
Aug 29, 2025

On August 25, 2025, TriSalus Life Sciences, Inc. approved an increase in the annual compensation of their Chief Financial Officer, Mr. David Patience, from $450,000 to $550,000. Additionally, on August 28, 2025, the company granted Mr. Patience stock options to purchase 249,899 shares of common stock, contingent upon the company achieving or exceeding $75 million in revenue over a twelve-month period before the end of 2027.

Delistings and Listing ChangesBusiness Operations and Strategy
TriSalus Completes Exchange Offer for Preferred Stock
Positive
Jul 24, 2025

TriSalus Life Sciences announced the completion of its exchange offer and consent solicitation for its Series A Convertible Preferred Stock, which expired on July 23, 2025. The company received consent from 98.82% of preferred stockholders to exchange their shares for common stock, allowing the adoption of a Preferred Stock Amendment that facilitates conversion of remaining preferred shares into common stock, thereby impacting its capital structure and potentially enhancing shareholder value.

Private Placements and FinancingBusiness Operations and Strategy
TriSalus Launches Exchange Offer for Preferred Stock
Neutral
Jun 23, 2025

On June 23, 2025, TriSalus Life Sciences announced the commencement of an exchange offer and consent solicitation for its Series A Convertible Preferred Stock. This initiative aims to streamline the company’s capital structure by allowing preferred shareholders to exchange their shares for common stock, thereby reducing potential dilution and improving transparency in equity value. Approximately 55% of preferred shareholders have agreed to the exchange and proposed amendments, which, if approved, will enable automatic conversion of remaining preferred shares into common stock. The offer is set to expire on July 23, 2025, and is contingent on certain conditions being met.

Executive/Board ChangesShareholder Meetings
TriSalus Life Sciences Holds Annual Shareholder Meeting
Neutral
Jun 16, 2025

On June 12, 2025, TriSalus Life Sciences, Inc. held its Annual Meeting of Shareholders, where 73.2% of the total outstanding shares were represented. During the meeting, two directors were elected for three-year terms, and the appointment of Grant Thornton, LLP as the independent registered accounting firm for 2025 was ratified.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025